GlassScriptPhysician profile
Bryan J Badik
NPI 1669405213
$3,461.84
in general payments reported to CMS, 2019-2025
31 companies · $32.38 in 2025
The $32.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $371 · 2021: $45.43 · 2022: $904 · 2023: $309 · 2025: $32.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $772.58 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $376.32 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $297.58 | 2019-2022 | |
| Abbvie INC. | $281.91 | 2022-2023 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $225.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $194.42 | 2019-2021 | |
| Amgen INC. | $178.10 | 2019-2025 | Evenity |
| Amarin Pharma, INC. | $152.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.12 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $97.88 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $80.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $75.13 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.02 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $57.11 | 2022-2023 | |
| Lilly USA, LLC | $44.14 | 2019-2023 | Mounjaro |
| Allergan, INC. | $39.67 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $29.41 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $26.32 | 2022 | |
| The Binding Site INC. | $25.00 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $20.04 | 2023 | Opsumit, Uptravi |
| Abbott Laboratories | $18.88 | 2019 | |
| Cordis US Corp. | $17.91 | 2025 | Brite Tip Radianz |
| Genentech USA, INC. | $17.51 | 2019 | |
| Hikma Pharmaceuticals USA | $14.89 | 2019 | |
| Daiichi Sankyo INC. | $14.57 | 2021 | |
| Bausch Health US, LLC | $14.36 | 2022 | |
| Neos Therapeutics, LP | $13.50 | 2022 | |
| Shire North American Group INC | $12.48 | 2019 | |
| Eisai INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Badik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.